Guest guest Posted February 28, 2011 Report Share Posted February 28, 2011 I'm interested in a comparison of the effect of each of these drugs, as understood right now in these early days. My understanding is that CAL-101 has been around a bit longer and is now in Phase II trials combined with R and perhaps O or other monoclonals, while PCI-32765 is Phase I or Ib by itself and perhaps now being, or about to be, tried in combination? I know they are both kinase inhibitors, but would love to see a discussion of where each seems to work best (nodes, spleen, marrow, blood). Also, I think Ramona brings up an interesting point for those of us who are on the edge of the treatment pit, but haven't toppled in yet. (Sorry for the weird metaphor.) Dr. Furman, do you think more trials will continue to open for the untreated elderly for both of these drugs? I can imagine the drug company can only afford so many trials and then it has to get into the business of making some money. For Calistoga, clearly the paradigm was to show remarkable results and get bought. But now the new owner needs to start to see how to profit and the FDA is somewhere on that path. I don't see how we go from trial to prescription for these impressive new treatments. Dr. Furman, do you have a vision here to share? Lots of questions in this post .. Should I have made three different posts? Hope all will be revealed, as much as is possible in the ever changing unpredictable world of CLL. Lynn Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.